Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Cerebrospinal fluid neurofilament light levels in neurodegenerative dementia: Evaluation of diagnostic accuracy in the differential diagnosis of prion diseases

  • Zerr, Inga
  • Schmitz, Matthias
  • Karch, André
  • Villar Piqué, Anna
  • Kanata, Eirini
  • Golanska, Ewa
  • Diaz-Lucena, Daniela
  • Llorens Torres, Franc
  • Hermann, Peter
  • Knipper, Tobias
  • Goebel, Stefan
  • Varges, Daniela
  • Sklaviadis, Theodoros
  • Sikorska, Beata
  • Liberski, Pawel P.
  • Ladogana, Anna
  • Ferrer, Isidro (Ferrer Abizanda)
  • Zetterberg, Henrik
  • Blennow, Kaj
  • Calero, Miguel
  • Sánchez del Valle Díaz, Raquel
  • Baldeiras, Inês
Introduction: neurofilament light (NFL) levels in the cerebrospinal fluid are increased in several neurodegenerative dementias. However, their diagnostic accuracy in the differential diagnostic context is unknown. Methods: cerebrospinal fluid NFL levels were quantified in nonprimarily neurodegenerative neurological and psychiatric diseases (n = 122), mild cognitive impairment (n = 48), Alzheimer's disease (n = 108), dementia with Lewy bodies/Parkinson's disease dementia (n = 53), vascular dementia (n = 46), frontotemporal dementia (n = 41), sporadic Creutzfeldt-Jakob disease (sCJD, n = 132), and genetic prion diseases (n = 182). Results: the highest NFL levels were detected in sCJD, followed by vascular dementia, frontotemporal dementia, dementia with Lewy bodies/Parkinson's disease dementia, Alzheimer's disease, and mild cognitive impairment. In sCJD, NFL levels correlated with cerebrospinal fluid tau and disease duration. NFL levels were able to differentiate sCJD from nonprimarily neurodegenerative neurological and psychiatric diseases (area under the curve = 0.99, 95% confidence interval: 0.99-1) and from the other diagnostic groups showing cognitive impairment/dementia of a non-CJD etiology (area under the curve = 0.90, 95% confidence interval: 0.87-0.92). Compared to nonprimarily neurodegenerative neurological and psychiatric diseases, NFL was also elevated in genetic prion diseases associated with the E200K, V210I, P102L, and D178N prion protein gene mutations. Discussion: increased NFL levels are a common feature in neurodegenerative dementias.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Cerebrospinal fluid lipocalin 2 as a novel biomarker for the differential diagnosis of vascular dementia

  • Llorens Torres, Franc
  • Hermann, Peter
  • Villar Piqué, Anna
  • Diaz Lucena, Daniela
  • Nägga, Katarina
  • Hansson, Oskar
  • Santana, Isabel
  • Schmitz, Matthias
  • Schmidt, Christian
  • Varges, Daniela
  • Goebel, Stefan
  • Dumurgier, Julien
  • Zetterberg, Henrik
  • Blennow, Kaj
  • Paquet, Claire
  • Baldeiras, Inês
  • Ferrer, Isidro (Ferrer Abizanda)
  • Zerr, Inga
The clinical diagnosis of vascular dementia (VaD) is based on imaging criteria, and specific biochemical markers are not available. Here, we investigated the potential of cerebrospinal fluid (CSF) lipocalin 2 (LCN2), a secreted glycoprotein that has been suggested as mediating neuronal damage in vascular brain injuries. The study included four independent cohorts with a total n = 472 samples. LCN2 was significantly elevated in VaD compared to controls, Alzheimer's disease (AD), other neurodegenerative dementias, and cognitively unimpaired patients with cerebrovascular disease. LCN2 discriminated VaD from AD without coexisting VaD with high accuracy. The main findings were consistent over all cohorts. Neuropathology disclosed a high percentage of macrophages linked to subacute infarcts, reactive astrocytes, and damaged blood vessels in multi-infarct dementia when compared to AD. We conclude that CSF LCN2 is a promising candidate biochemical marker in the differential diagnosis of VaD and neurodegenerative dementias.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Control of glutamate release by complexes of adenosine and cannabinoid receptors

  • Köfalvi, Attila
  • Moreno Guillén, Estefanía
  • Cordomí, Arnau
  • Cai, Ning-Sheng
  • Fernández Dueñas, Víctor
  • Ferreira, Samira G.
  • Guixà-González, Ramón
  • Sánchez Soto, Marta
  • Yano, Hideaki
  • Casadó Anguera, Verònica
  • Cunha, Rodrigo A.
  • Sebastião, Ana Maria
  • Ciruela Alférez, Francisco
  • Pardo, Leonardo
  • Casadó, Vicent
  • Ferré, Sergi
Background It has been hypothesized that heteromers of adenosine A2A receptors (A2AR) and cannabinoid CB1 receptors (CB1R) localized in glutamatergic nerve terminals mediate the integration of adenosine and endocannabinoid signaling involved in the modulation of striatal excitatory neurotransmission. Previous studies have demonstrated the existence of A2AR-CB1R heteromers in artificial cell systems. A dependence of A2AR signaling for the Gi protein-mediated CB1R signaling was described as one of its main biochemical characteristics. However, recent studies have questioned the localization of functionally significant A2AR-CB1R heteromers in striatal glutamatergic terminals. Results Using a peptide-interfering approach combined with biophysical and biochemical techniques in mammalian transfected cells and computational modeling, we could establish a tetrameric quaternary structure of the A2AR-CB1R heterotetramer. This quaternary structure was different to the also tetrameric structure of heteromers of A2AR with adenosine A1 receptors or dopamine D2 receptors, with different heteromeric or homomeric interfaces. The specific quaternary structure of the A2A-CB1R, which depended on intermolecular interactions involving the long C-terminus of the A2AR, determined a significant A2AR and Gs protein-mediated constitutive activation of adenylyl cyclase. Using heteromer-interfering peptides in experiments with striatal glutamatergic terminals, we could then demonstrate the presence of functionally significant A2AR-CB1R heteromers with the same biochemical characteristics of those studied in mammalian transfected cells. First, either an A2AR agonist or an A2AR antagonist allosterically counteracted Gi-mediated CB1R agonist-induced inhibition of depolarization-induced glutamate release. Second, co-application of both an A2AR agonist and an antagonist cancelled each other effects. Finally, a CB1R agonist inhibited glutamate release dependent on a constitutive activation of A2AR by a canonical Gs-Gi antagonistic interaction at the adenylyl cyclase level. Conclusions We demonstrate that the well-established cannabinoid-induced inhibition of striatal glutamate release can mostly be explained by a CB1R-mediated counteraction of the A2AR-mediated constitutive activation of adenylyl cyclase in the A2AR-CB1R heteromer.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Prosocial behaviors in rodents

  • Gachomba, Michael J. M.
  • Esteve-Agraz, Joan
  • Márquez, Cristina
Prosocial behaviors (i.e., actions that benefit others) are central for social interactions in humans and other animals, by fostering social bonding and cohesion. To study prosociality in rodents, scientists have developed behavioral paradigms where animals can display actions that benefit conspecifics in distress or need. These paradigms have provided insights into the role of social interactions and transfer of emotional states in the expression of prosociality, and increased knowledge of its neural bases. However, prosociality levels are variable: not all tested animals are prosocial. Such variation has been linked to differences in animals' ability to process another's state as well as to contextual factors. Moreover, evidence suggests that prosocial behaviors involve the orchestrated activity of multiple brain regions and neuromodulators. This review aims to synthesize findings across paradigms both at the level of behavior and neural mechanisms. Growing evidence confirms that these processes can be studied in rodents, and intense research in the past years is rapidly advancing our knowledge. We discuss a strong bias in the field towards the study of these processes in negative valence contexts (e.g., pain, fear, stress), which should be taken as an opportunity to open new venues for future research., This work was supported by the DYNABrain ERA Chair project (to CM as ERA Chair holder) which has received funding from the European Union’s Horizon 2020 research and innovation programme under Grant Agreement no. 952422. The funders had no role in preparation of the manuscript., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Cerebrospinal fluid lipocalin 2 as a novel biomarker for the differential diagnosis of vascular dementia

  • Llorens Torres, Franc
  • Hermann, Peter
  • Villar Piqué, Anna
  • Diaz Lucena, Daniela
  • Nägga, Katarina
  • Hansson, Oskar
  • Santana, Isabel
  • Schmitz, Matthias
  • Schmidt, Christian
  • Varges, Daniela
  • Goebel, Stefan
  • Dumurgier, Julien
  • Zetterberg, Henrik
  • Blennow, Kaj
  • Paquet, Claire
  • Baldeiras, Inês
  • Ferrer, Isidro (Ferrer Abizanda)
  • Zerr, Inga
The clinical diagnosis of vascular dementia (VaD) is based on imaging criteria, and specific biochemical markers are not available. Here, we investigated the potential of cerebrospinal fluid (CSF) lipocalin 2 (LCN2), a secreted glycoprotein that has been suggested as mediating neuronal damage in vascular brain injuries. The study included four independent cohorts with a total n = 472 samples. LCN2 was significantly elevated in VaD compared to controls, Alzheimer's disease (AD), other neurodegenerative dementias, and cognitively unimpaired patients with cerebrovascular disease. LCN2 discriminated VaD from AD without coexisting VaD with high accuracy. The main findings were consistent over all cohorts. Neuropathology disclosed a high percentage of macrophages linked to subacute infarcts, reactive astrocytes, and damaged blood vessels in multi-infarct dementia when compared to AD. We conclude that CSF LCN2 is a promising candidate biochemical marker in the differential diagnosis of VaD and neurodegenerative dementias.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Cerebrospinal fluid neurofilament light levels in neurodegenerative dementia: Evaluation of diagnostic accuracy in the differential diagnosis of prion diseases

  • Zerr, Inga
  • Schmitz, Matthias
  • Karch, André
  • Villar Piqué, Anna
  • Kanata, Eirini
  • Golanska, Ewa
  • Diaz-Lucena, Daniela
  • Llorens Torres, Franc
  • Hermann, Peter
  • Knipper, Tobias
  • Goebel, Stefan
  • Varges, Daniela
  • Sklaviadis, Theodoros
  • Sikorska, Beata
  • Liberski, Pawel P.
  • Ladogana, Anna
  • Ferrer, Isidro (Ferrer Abizanda)
  • Zetterberg, Henrik
  • Blennow, Kaj
  • Calero, Miguel
  • Sánchez del Valle Díaz, Raquel
  • Baldeiras, Inês
Introduction: neurofilament light (NFL) levels in the cerebrospinal fluid are increased in several neurodegenerative dementias. However, their diagnostic accuracy in the differential diagnostic context is unknown. Methods: cerebrospinal fluid NFL levels were quantified in nonprimarily neurodegenerative neurological and psychiatric diseases (n = 122), mild cognitive impairment (n = 48), Alzheimer's disease (n = 108), dementia with Lewy bodies/Parkinson's disease dementia (n = 53), vascular dementia (n = 46), frontotemporal dementia (n = 41), sporadic Creutzfeldt-Jakob disease (sCJD, n = 132), and genetic prion diseases (n = 182). Results: the highest NFL levels were detected in sCJD, followed by vascular dementia, frontotemporal dementia, dementia with Lewy bodies/Parkinson's disease dementia, Alzheimer's disease, and mild cognitive impairment. In sCJD, NFL levels correlated with cerebrospinal fluid tau and disease duration. NFL levels were able to differentiate sCJD from nonprimarily neurodegenerative neurological and psychiatric diseases (area under the curve = 0.99, 95% confidence interval: 0.99-1) and from the other diagnostic groups showing cognitive impairment/dementia of a non-CJD etiology (area under the curve = 0.90, 95% confidence interval: 0.87-0.92). Compared to nonprimarily neurodegenerative neurological and psychiatric diseases, NFL was also elevated in genetic prion diseases associated with the E200K, V210I, P102L, and D178N prion protein gene mutations. Discussion: increased NFL levels are a common feature in neurodegenerative dementias.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Control of glutamate release by complexes of adenosine and cannabinoid receptors

  • Köfalvi, Attila
  • Moreno Guillén, Estefanía
  • Cordomí, Arnau
  • Cai, Ning-Sheng
  • Fernández Dueñas, Víctor
  • Ferreira, Samira G.
  • Guixà-González, Ramón
  • Sánchez Soto, Marta
  • Yano, Hideaki
  • Casadó Anguera, Verònica
  • Cunha, Rodrigo A.
  • Sebastião, Ana Maria
  • Ciruela Alférez, Francisco
  • Pardo, Leonardo
  • Casadó, Vicent
  • Ferré, Sergi
Background It has been hypothesized that heteromers of adenosine A2A receptors (A2AR) and cannabinoid CB1 receptors (CB1R) localized in glutamatergic nerve terminals mediate the integration of adenosine and endocannabinoid signaling involved in the modulation of striatal excitatory neurotransmission. Previous studies have demonstrated the existence of A2AR-CB1R heteromers in artificial cell systems. A dependence of A2AR signaling for the Gi protein-mediated CB1R signaling was described as one of its main biochemical characteristics. However, recent studies have questioned the localization of functionally significant A2AR-CB1R heteromers in striatal glutamatergic terminals. Results Using a peptide-interfering approach combined with biophysical and biochemical techniques in mammalian transfected cells and computational modeling, we could establish a tetrameric quaternary structure of the A2AR-CB1R heterotetramer. This quaternary structure was different to the also tetrameric structure of heteromers of A2AR with adenosine A1 receptors or dopamine D2 receptors, with different heteromeric or homomeric interfaces. The specific quaternary structure of the A2A-CB1R, which depended on intermolecular interactions involving the long C-terminus of the A2AR, determined a significant A2AR and Gs protein-mediated constitutive activation of adenylyl cyclase. Using heteromer-interfering peptides in experiments with striatal glutamatergic terminals, we could then demonstrate the presence of functionally significant A2AR-CB1R heteromers with the same biochemical characteristics of those studied in mammalian transfected cells. First, either an A2AR agonist or an A2AR antagonist allosterically counteracted Gi-mediated CB1R agonist-induced inhibition of depolarization-induced glutamate release. Second, co-application of both an A2AR agonist and an antagonist cancelled each other effects. Finally, a CB1R agonist inhibited glutamate release dependent on a constitutive activation of A2AR by a canonical Gs-Gi antagonistic interaction at the adenylyl cyclase level. Conclusions We demonstrate that the well-established cannabinoid-induced inhibition of striatal glutamate release can mostly be explained by a CB1R-mediated counteraction of the A2AR-mediated constitutive activation of adenylyl cyclase in the A2AR-CB1R heteromer.